Clinical trials: Molecular Diagnosis
Hyperlipidemias
Plasma Lipid Response to Glucose Drink
During dietary fat absorption, the gut packages the majority of the fats into lipid particles that are secreted into blood circulation.
- Trial name
- NCT03435432
- Testing
- Glucose, Water
- Where
- Canada
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Atrophic Vaginitis
Oral Low-molecular Weight Hyaluronic Acid in the Treatment of Atrophic Vaginitis
To evaluate the effectiveness of low molecular weight hyaluronic acid oral tablets for the treatment of atrophic vaginitis.
- Trial name
- NCT02014428
- Testing
- Hyaluronic acid
- Where
- Italy
- Sponsor
- AGUNCO Obstetrics and Gynecology Centre
Glioblastoma, Astrocytoma, Grade IV
A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM
The purpose of the Cerebral EDV study is to determine the safety and tolerability of EGFR(V)-EDV-Dox in order to establish the best dose level to be used in future studies.
- Trial name
- CerebralEDV (NCT02766699)
- Testing
- EGFR(V)-EDV-Dox
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Engeneic Pty Limited
Oesophageal Cancer, Gastric Cancer
Upper GI Serial Tumour Biopsies
This is a prospective translational research study in which tumour samples, blood samples and other biospecimens will be requested from patients with locally advanced or metastatic malignant oesophageal and gastric carcinoma.
- Trial name
- NCT05233007
- Testing
- Minor endoscopic biopsy
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- The Christie NHS Foundation Trust
Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE)
Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)
Evaluation of the safety and effectiveness of ActiveCare+ CECT device +/- baby dose aspirin (81 mg QD) for lowering the potential risk for bleeding and of DVT during and after THA surgery in comparison with LMWH.
- Conditions
- Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
- Trial name
- SAFE (NCT00358735)
- Testing
- ActiveCare CECT device, Enoxaparin
- Where
- 9 sites in United States
- Volunteers
- 411 people
- Sponsor
- Medical Compression Systems
Colon Cancer, Immunotherapy
Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC
To compare the efficacy and safety of tirellizumab combined with anlotinib in the treatment of mss colorectal cancer. To investigate the effective biomarker of anlotinib combined with tiralizumab
- Trial name
- NCT06573424
- Testing
- Tislelizumab+anlotinib, anlotinib
- Where
- China
- Volunteers
- 124 people
- Sponsor
- fan li
Rhabdomyosarcoma
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
This is a phase II study to determine safety and efficacy of combining liposomal irinotecan with vincristine alternating with VAC in intermediate-risk patients, liposomal irinotecan with temozolomide and vincristine alternating…
- Trial name
- NCT06023641
- Testing
- Vincristine, Dactinomycin, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- St. Jude Children's Research Hospital
Pancreatic Cancer
Identification of Biomarkers for Early Detection of Pancreatic Cancer
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897494
- Testing
- protein expression analysis, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Glycogen Storage Disease Type II, Adult
Natural History of Pompe Disease
The project is a prospective study in which patients affected by adult-onset Pompe disease with c.-32-13T>G mutation in the GAA gene will be followed-up during two years to describe the natural history using clinical, imaging…
- Trial name
- POMPE (NCT03564561)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Neoplasms, Breast Cancer
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
- Conditions
- Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
- Trial name
- NCT05113251
- Testing
- Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab
- Where
- 145 sites in United States, Brazil and 16 more
- Volunteers
- 927 people
- Sponsor
- AstraZeneca
Fuchs Endothelial Corneal Dystrophy, FECD3
Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3
PQ-504a-001 (Fuchs Focus) is an open-label, single-dose, exploratory study to evaluate safety, tolerability, and corneal endothelium molecular biomarker(s) in subjects with Fuchs Endothelial Corneal Dystrophy with Trinucleotide…
- Conditions
- Fuchs Endothelial Corneal Dystrophy, FECD3, Corneal Diseases, LRS
- Trial name
- Fuchs Focus (NCT05052554)
- Testing
- QR-504a
- Where
- United Kingdom
- Sponsor
- ProQR Therapeutics
Major Depressive Disorder
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03357796
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Dravet Syndrome
EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity
Dravet syndrome is characterized as a developmental encephalopathy resulting from mutations of SCN1A, the gene encoding the alpha subunit of the voltage-gated sodium channel Nav1.1.
- Trial name
- EXEDRA (NCT06371794)
- Testing
- skin punch biopsy
- Where
- Italy
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hodgkin Disease, Lymphoma, Non-Hodgkin
Tissue Collection for Studies of Lymph Cancer
Background: Lab studies help researchers better understand cancer biology. This information may lead to new methods for diagnosing or treating cancer.
- Conditions
- Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphomatoid Granulomatosis
- Trial name
- NCT01676805
- Where
- 2 sites in United States, Jamaica
- Volunteers
- 1,295 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Obstructive Pulmonary Disease
Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels
The 3TR-ICS COPD study is an international, multicentre, randomized, parallel, controlled study that will recruit clinically stable former smokers COPD patients (with no exacerbations in the previous 8 weeks) on treatment with…
- Trial name
- 3TR-ICS-COPD (NCT06334575)
- Testing
- Budesonide
- Where
- 6 sites in Germany, Netherlands and 2 more
- Volunteers
- 135 people
- Sponsor
- Maria Joyera Rodríguez
Obesity
Medium-term Effects of Molecular Hydrogen on Metabolic Fitness in Obesity
Molecular hydrogen (H2) effectively tackles obesity-related disorders in animal models yet no studies so far investigated the effectiveness of H2 for improving biomarkers of obesity in humans.
- Trial name
- NCT02832219
- Testing
- Molecular hydrogen
- Where
- Serbia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Center for Health Sciences, Serbia
HER2-positive Breast Cancer
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer
The purpose of the study is to identify molecular markers at the level of molecular pathway activation to predict efficacy of anti-HER2 therapy with Trastuzumab.
- Trial name
- NCT03521245
- Testing
- RNA sequencing, Transcriptome analysis, Trastuzumab
- Where
- 4 sites in United States, Russia
- Volunteers
- 40 people
- Sponsor
- OmicsWay Corp.
Parkinson Disease, PARK8, Parkinson Disease
Molecular Pathology and Neuronal Networks in LRRK2 Parkinson's Disease
Parkinson's Disease (PD) is a progressive neurodegenerative disease characterized clinically by bradykinesia, resting tremor, rigidity, and postural instability.
- Conditions
- Parkinson Disease, PARK8, Parkinson Disease, Idiopathic Parkinson Disease
- Trial name
- NCT03782753
- Where
- United Kingdom
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- King's College London
Pregnancy Loss, Pregnancy Loss, Early
Efficacy of Progesterone and Low Molecular Weight Heparin in Recurrent Pregnancy Loss
This prospective, single-centre, open-label, randomized Phase III superiority trial will enroll approximately 268 women aged 18-40 years with at least two consecutive unexplained miscarriages and a singleton intrauterine…
- Trial name
- PREMISE (NCT07796737)
- Testing
- Vaginal Micronized Progesterone (Progesterone Besins), Enoxaparin (Clexane)
- Where
- Czechia
- Volunteers
- 268 people
- Sponsor
- General University Hospital, Prague
MSI, ColoRectal Cancer
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
The primary objective of this study is to determine the anti-tumor activity, as measured by overall response rate (ORR) of atezolizumab in combination with bevacizumab in patients with chemotherapy resistant CRC and positivity…
- Conditions
- MSI, ColoRectal Cancer, Chemotherapy, Resistance, APC
- Trial name
- NCT02982694
- Testing
- Atezolizumab, Bevacizumab
- Where
- 7 sites in Belgium, Italy and 2 more
- Volunteers
- 46 people
- Sponsor
- Vall d'Hebron Institute of Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.